Xencor, Inc.

ISIN US98401F1057

 | 

WKN A1W96L

Market cap (in EUR)
715 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Show more Show less
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 715 m
EPS, EUR -1.61
P/B ratio 1.4
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 102 m
Net income, EUR -215 m
Profit margin -210.53%

What ETF is Xencor, Inc. in?

There are 3 ETFs which contain Xencor, Inc.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Xencor, Inc. is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.10%
Equity
United States
Health Care
Biotech
46
iShares S&P SmallCap 600 UCITS ETF 0.07%
Equity
United States
Small Cap
2,169
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.02%
Equity
United States
Small Cap
190
— Les données utilisées sont mises à disposition par Trackinsight, etfinfo, Xignite Inc., gettex, FactSet et justETF GmbH.

Les cotations sont des cotations en temps réel (gettex), des cotations boursières retardées de 15 minutes ou des VNI (quotidiennes publiées par le fournisseur du fonds). Par défaut, les rendements des ETF incluent les paiements de dividendes (le cas échéant). Aucune garantie n'est donnée quant à l'exhaustivité, la précision et l'exactitude des informations affichées.